Phase I dose-escalation study of ZK 304709, an oral multi-target tumor growth inhibitor (MTGI), administered for 14 days of a 28-day cycle.

被引：0
|
作者：
Ahmed, S.
Molife, R.
Shaw, H.
Steward, W.
Thomas, A.
Barrett, M.
Kowal, K.
McCoy, C.
De-Bono, J.
机构：
[1] Leicester Royal Infirm, Leicester LE1 5WW, Leics, England
[2] ICR, Surrey, England
[3] Royal Marsden NHS Trust, Surrey, England
[4] Schering AG, D-1000 Berlin, Germany
[5] Berlex Inc, Seattle, WA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2006年 / 24卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：98S / 98S
页数：1
相关论文
共 35 条
  • [1] Phase I dose-escalation study of novel oral multi-target tumor growth inhibitor (MTGI) ZK 304709 administered daily for 7 days of a 21-day cycle to patients with advanced solid tumors.
    Graham, J.
    Wagner, K.
    Plummer, R.
    Wiedenmann, B.
    Cassidy, J.
    Kowal, K.
    McCoy, C.
    Calvert, H.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 97S - 97S
  • [2] A phase I dose escalation study of the pharmacokinetics and tolerability of ZK 304709, an oral multi-targeted growth inhibitor (MTGI™), in patients with advanced solid tumours
    Scott, Edwina N.
    Thomas, Anne L.
    Molife, L. Rhoda
    Ahmed, Samreen
    Blagden, Sarah
    Fong, Peter C.
    Kowal, Kristin
    McCoy, Candice
    Wiesinger, Herbert
    Steward, Will
    De Bono, Johann
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2009, 64 (02) : 425 - 429
  • [3] A phase I dose escalation study of the pharmacokinetics and tolerability of ZK 304709, an oral multi-targeted growth inhibitor (MTGI™), in patients with advanced solid tumours
    Edwina N. Scott
    Anne L. Thomas
    L. Rhoda Molife
    Samreen Ahmed
    Sarah Blagden
    Peter C. Fong
    Kristin Kowal
    Candice McCoy
    Herbert Wiesinger
    Will Steward
    Johann De Bono
    [J]. Cancer Chemotherapy and Pharmacology, 2009, 64 : 425 - 429
  • [4] The antitumor and antimetastasis effect of the oral Multi-target Tumor Growth Inhibitor™, ZK 304709, in pancreatic tumor xenografts
    Siemeister, Gerhard
    Detjen, Katharina
    Kaekoenen, Sanna-Maria
    Luecking, Ulrich
    Mumberg, Domink
    Scholz, Arne
    Wagner, Karola
    Wiedenmann, Bertram
    Bosslet, Klaus
    [J]. CANCER RESEARCH, 2006, 66 (08)
  • [5] ZK 304709, the multi-target tumor growth Inhibitor™ (MTGI™), inhibits osteolysis and tumor burden in a breast cancer bone metastasis model.
    Käkönen, S.
    Bosslet, K.
    Siemeister, G.
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 2006, 21 : S28 - S28
  • [6] ZK 304709, the oral multi-target tumor growth inhibitor tm, inhibits primary tumor growth and metastasis formation in pancreatic tumor xenograft models.
    Siemeister, G
    Detjen, K
    Hennekes, H
    Kaekoenen, S
    Scholz, A
    Wagner, K
    Wiedenmann, B
    Bosslet, K
    [J]. CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9111S - 9112S
  • [7] Phase I dose-escalation and pharmacokinetic study of ispinesib, a kinesin spindle protein inhibitor, administered on days 1 and 15 of a 28-day schedule in patients with no prior treatment for advanced breast cancer
    Gomez, Henry L.
    Philco, Manuel
    Pimentel, Patricia
    Kiyan, Miriam
    Monsalvo, Maria Laura
    Conlan, Maureen G.
    Saikali, Khalil G.
    Chen, Michael M.
    Seroogy, Joseph J.
    Wolff, Andrew A.
    Escandon, Rafael D.
    [J]. ANTI-CANCER DRUGS, 2012, 23 (03) : 335 - 341
  • [8] A dose-escalation phase I study of oral pan-CDK inhibitor BAY 1000394 in patients with advanced solid tumors: Dose escalation with an intermittent 28 days on/14 days off schedule
    Grilley-Olson, Juneko E.
    Weiss, Glen J.
    Rajagopalan, Prabhu
    Henderson, David Andrew
    Kornacker, Martin
    Govindan, Ramaswamy
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [9] Phase I dose escalation study of the Aurora kinase inhibitor PHA-739358 administered as a 24 hours infusion in a 14-day cycle in patients with advanced/metastatic solid tumor
    Burris, H. A.
    Hudes, G.
    Jones, S.
    Cheng, J.
    Spigel, D.
    Mariani, M.
    Macdonald, H.
    Rocchetti, M.
    Laffranchi, B.
    Cohen, R. B.
    [J]. EJC SUPPLEMENTS, 2006, 4 (12): : 107 - 107
  • [10] A phase I study of ispinesib, a kinesin spindle protein inhibitor, administered weekly for three consecutive weeks of a 28-day cycle in patients with solid tumors
    Burris, Howard A., III
    Jones, Suzanne F.
    Williams, Daphne D.
    Kathman, Steven J.
    Hodge, Jeffrey P.
    Pandite, Lini
    Ho, Peter T. C.
    Boerner, Scott A.
    LoRusso, Patricia
    [J]. INVESTIGATIONAL NEW DRUGS, 2011, 29 (03) : 467 - 472
1234